120 related articles for article (PubMed ID: 24211751)
1. Anti-inflammatory interventions in end-stage kidney disease: a randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis.
Cueto-Manzano AM; Angel-Zúñiga JR; Ornelas-Carrillo G; Rojas-Campos E; Martínez-Ramírez HR; Cortés-Sanabria L
Arch Med Res; 2013 Nov; 44(8):633-7. PubMed ID: 24211751
[TBL] [Abstract][Full Text] [Related]
2. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
Albert MA; Danielson E; Rifai N; Ridker PM;
JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients.
Yongsiri S; Thammakumpee J; Prongnamchai S; Tengpraettanakorn P; Chueansuwan R; Tangjaturonrasme S; Dinchuthai P
Ther Apher Dial; 2015 Feb; 19(1):81-6. PubMed ID: 25196890
[TBL] [Abstract][Full Text] [Related]
4. Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients.
Tekin IO; Pocan B; Borazan A; Ucar E; Kuvandik G; Ilikhan S; Demircan N; Ozer C; Kadayifci S
Ren Fail; 2008; 30(2):219-25. PubMed ID: 18300125
[TBL] [Abstract][Full Text] [Related]
5. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
Taheri S; Mortazavi M; Pourmoghadas A; Seyrafian S; Alipour Z; Karimi S
Saudi J Kidney Dis Transpl; 2012 May; 23(3):507-12. PubMed ID: 22569436
[TBL] [Abstract][Full Text] [Related]
6. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis.
Saltissi D; Morgan C; Rigby RJ; Westhuyzen J
Am J Kidney Dis; 2002 Feb; 39(2):283-90. PubMed ID: 11840368
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients.
Sezer S; Tutal E; Arat Z; Akçay A; Celik H; Ozdemir FN; Haberal M
J Ren Nutr; 2005 Oct; 15(4):427-34. PubMed ID: 16198934
[TBL] [Abstract][Full Text] [Related]
9. Ischemia-modified albumin, a predictive marker of major adverse cardiovascular events in continuous ambulatory peritoneal dialysis patients.
Su X; Zhang K; Guo F; Yuan B; Wang C; Xiao L; Wang J; Huang H
Clin Biochem; 2013 Oct; 46(15):1410-3. PubMed ID: 23796881
[TBL] [Abstract][Full Text] [Related]
10. Pilot randomized trial of short-term changes in inflammation and lipid levels during and after aspirin and pravastatin therapy.
Flannagan KS; Sjaarda LA; Hill MJ; Connell MT; Zolton JR; Perkins NJ; Mumford SL; Plowden TC; Andriessen VC; Radoc JG; Schisterman EF
Reprod Health; 2019 Sep; 16(1):132. PubMed ID: 31477152
[TBL] [Abstract][Full Text] [Related]
11. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
[TBL] [Abstract][Full Text] [Related]
12. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Harris KP; Wheeler DC; Chong CC;
Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
[TBL] [Abstract][Full Text] [Related]
13. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.
Li Y; Xie QH; You HZ; Tian J; Hao CM; Lin SY; Zhu TY
Perit Dial Int; 2012; 32(5):507-15. PubMed ID: 22383630
[TBL] [Abstract][Full Text] [Related]
14. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
[TBL] [Abstract][Full Text] [Related]
15. [Effect of zinc supplements on the nutritional status of patients undergoing continuous ambulatory peritoneal dialysis].
Munguía C; Paniagua R; Avila-Díaz M; Nava-Hernández J; Rodríguez E; Ventura Mde J; Amato D
Rev Invest Clin; 2003; 55(5):519-27. PubMed ID: 14968473
[TBL] [Abstract][Full Text] [Related]
16. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia.
Morris R; Robinson G; Tilyard M; Gurr E
N Z Med J; 1996 Aug; 109(1028):319-22. PubMed ID: 8816723
[TBL] [Abstract][Full Text] [Related]
17. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Lewis JH; Mortensen ME; Zweig S; Fusco MJ; Medoff JR; Belder R;
Hepatology; 2007 Nov; 46(5):1453-63. PubMed ID: 17668878
[TBL] [Abstract][Full Text] [Related]
19. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Ridker PM; Morrow DA; Rose LM; Rifai N; Cannon CP; Braunwald E
J Am Coll Cardiol; 2005 May; 45(10):1644-8. PubMed ID: 15893181
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of inflammation and progression of chronic kidney disease.
Tonelli M; Sacks F; Pfeffer M; Jhangri GS; Curhan G;
Kidney Int; 2005 Jul; 68(1):237-45. PubMed ID: 15954913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
